Ongoing Studies

Ongoing Studies

ARIES (BAY86-5321/17508) A phase IV/IIIb study managing neovascular age-related macular degeneration (nAMD) over 2 years with a treat and extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study.

CENTERA (BAY86--5321/17514) A multi-center, single-arm, interventional phase 4 study to evaluate a treat and extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion.

KITE (CRTH258B2302) A two-year, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema.

KESTREL (CRTH258B2301) A two-year, three-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema.

LIGHTSITE II (CSP003) A double masked, randomized, sham-controlled, parallel group, multi-center study to assess the safety and efficacy of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD).

OCRELIZUMAB (WA25046) A phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of Ocrelizumab in adults with primary progressive multiple sclerosis.

OCRELIZUMAB (WA21092, WA21093) A phase III randomized, double-blinded, double dummy, parallel-group study to evaluate the efficacy and safety of Ocrelizumab in comparison to interferon beta-1a (Rebif®) in patients with relapsing multiple sclerosis.

RAPTOR (CRTH258C2301) An eighteen-month, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to branch retinal vein occlusion.

RAVEN (CRTH258C2302) An eighteen-month, two-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to central retinal vein occlusion.

TONE (EudraCt No.: 2013-002515-10) A phase III study for treatment of optic neuritis with erythropoietin: a randomised, double-blind, placebo-controlled trial; TONE (P000053).

TOLERANT STUDY A phase IV randomised, controlled study investigating the efficacy and safety of aflibercept “Treat and Extend” using a strict retreatment regimen compared to a relaxed retreatment regimen in patients with exudative age-related macular degeneration (AMD).